CEReSS-Health Service Research and Quality of Life Center, Assistance Publique-Hopitaux de Marseille, Aix-Marseille University, Marseille, France; Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khoramabad, Iran; Department of Physical Education and Sport Sciences, Faculty of Literature and Humanities, Vali-E-Asr University of Rafsanjan, Rafsanjan, Iran.
Centre for Health, Performance, and Wellbeing, Anglia Ruskin University, Cambridge, United Kingdom.
Ageing Res Rev. 2024 Nov;101:102523. doi: 10.1016/j.arr.2024.102523. Epub 2024 Oct 5.
Vision impairment (VI) and eye diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and cataract have been reported to be associated with cognitive impairment and dementia, however, to date, very little attempt has been made to collate and synthesizes such literature. Therefore, the aim of this umbrella review is to systematically assesses the credibility and certainty of evidence of associations between vision impairment (VI) and eye diseases with cognitive impairment, dementia and dementia subtypes. We conducted an umbrella review of meta-analyses by screening articles in any language in PubMed, MEDLINE (Ovid), EMBASE, Web of Science, Cochrane CENTRAL and CDSR published from database inception up to May 30, 2024. Quality appraisal of each included original meta-analysis was assessed using A Measurement Tool for Assessing Systematic Reviews 2 (AMSTAR2). The certainty of the evidence was based on statistical significance, study size, heterogeneity, small study effects, prediction intervals (PI), and bias. We followed an a-priori protocol registered with PROSPERO (CRD42024564249). We identified 13 meta-analyses (AMSTAR 2; high accuracy of the findings 1, moderate 10, and low 2) that included 232 original articles based on 99,337,354 participants. Overall, no evidence was highly suggestive or convincing. Suggestive evidence was found for associations between cataract and dementia (equivalent odds ratio [eOR] 1.20, 95 %CI, 1.16-1.25), cataract and Alzheimer's disease (eOR 1.21, 95 %CI, 1.15-1.28), and AMD and Alzheimer's disease (eOR 1.27, 95 %CI, 1.27-1.27). Weak evidence was found for associations between VI and dementia (eOR 1.50, 95 %CI, 1.23-1.84), DR and dementia (eOR 1.33, 95 %CI, 1.17-1.50), cataract and vascular dementia (eOR 1.26, 95 %CI, 1.09-1.45), VI identified by cross-sectional studies and cognitive impairment (eOR 2.37, 95 %CI, 2.31-2.44), and VI identified by objective measures and cognitive impairment (eOR 1.56, 95 %CI, 1.12-2.18). The observed suggestive level of evidence for the relationship between eye disease and dementia (as well as dementia subtypes) suggests that policy and interventions to aid in the prevention and management of eye disease may also aid in the prevention of dementia syndrome. Where the level of evidence is weak, further studies are needed with stronger methodological approaches.
视力障碍(VI)和眼部疾病,如年龄相关性黄斑变性(AMD)、糖尿病视网膜病变(DR)、青光眼和白内障,与认知障碍和痴呆有关,但迄今为止,很少有尝试对这些文献进行整理和综合。因此,本伞式综述的目的是系统评估与认知障碍、痴呆和痴呆亚型相关的视力障碍(VI)和眼部疾病关联的证据的可信度和确定性。我们通过筛选任何语言的文章,在 PubMed、MEDLINE(Ovid)、EMBASE、Web of Science、Cochrane CENTRAL 和 CDSR 中进行了伞式综述,这些文章从数据库开始到 2024 年 5 月 30 日发表。使用 A Measurement Tool for Assessing Systematic Reviews 2(AMSTAR2)评估每个纳入的原始荟萃分析的质量评估。证据的确定性基于统计学意义、研究规模、异质性、小研究效应、预测区间(PI)和偏倚。我们遵循了在 PROSPERO(CRD42024564249)中预先注册的方案。我们确定了 13 项荟萃分析(AMSTAR 2;高准确性发现 1 项,中等准确性发现 10 项,低准确性发现 2 项),其中包括基于 99337354 名参与者的 232 篇原始文章。总体而言,没有证据高度提示或令人信服。有提示性证据表明白内障与痴呆(等效优势比[eOR]1.20,95%CI,1.16-1.25)、白内障与阿尔茨海默病(eOR 1.21,95%CI,1.15-1.28)和 AMD 与阿尔茨海默病(eOR 1.27,95%CI,1.27-1.27)之间存在关联。与 VI 和痴呆(eOR 1.50,95%CI,1.23-1.84)、DR 和痴呆(eOR 1.33,95%CI,1.17-1.50)、白内障和血管性痴呆(eOR 1.26,95%CI,1.09-1.45)、横断面研究和认知障碍(eOR 2.37,95%CI,2.31-2.44)以及客观测量和认知障碍(eOR 1.56,95%CI,1.12-2.18)之间存在关联的证据较弱。眼病与痴呆(以及痴呆亚型)之间关系的观察到的提示性证据水平表明,为预防和管理眼病而采取的政策和干预措施也可能有助于预防痴呆综合征。在证据水平较弱的情况下,需要采用更强的方法学方法进行进一步研究。